{"id":9175,"date":"2025-11-12T12:33:35","date_gmt":"2025-11-12T09:33:35","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9175"},"modified":"2025-11-12T12:33:35","modified_gmt":"2025-11-12T09:33:35","slug":"metformin-for-atrial-fibrillation-aha-2025-meta-af-trial","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/metformin-for-atrial-fibrillation-aha-2025-meta-af-trial\/","title":{"rendered":"Metformin for Atrial Fibrillation \u2014 AHA 2025 (META-AF Trial)"},"content":{"rendered":"<div>Metformin for Atrial Fibrillation \u2014 AHA 2025 (META-AF Trial)<\/div>\n<div>Source: AHA\u00a0 Medical News, AHA Scientific Sessions 2025 ( Nov 11, 2025)<\/div>\n<div><\/div>\n<div>Key Points<\/div>\n<div><span> 1. Background:<\/span><\/div>\n<div><span> \u2022 Metformin, a long-used antidiabetic drug, may help reduce recurrent atrial arrhythmias after catheter ablation in overweight or obese patients without diabetes.<\/span><\/div>\n<div><span> 2. Study Design:<\/span><\/div>\n<div><span> \u2022 META-AF was a randomized, open-label trial including 99 patients (49 metformin, 50 control).<\/span><\/div>\n<div><span> \u2022 Participants were overweight\/obese, non-diabetic, and followed for 1 year after AF ablation.<\/span><\/div>\n<div><span> \u2022 Metformin started up to 6 weeks pre-ablation, titrated to max tolerated dose, continued for 12 months.<\/span><\/div>\n<div><span> 3. Main Findings:<\/span><\/div>\n<div><span> \u2022 Freedom from recurrent AF\/atrial arrhythmia:<\/span><\/div>\n<div><span> \u2022 Metformin group: 78%<\/span><\/div>\n<div><span> \u2022 Control group: 58%<\/span><\/div>\n<div><span> \u2022 AF burden (days with AF): 8% (metformin) vs 16% (control), P = 0.02.<\/span><\/div>\n<div><span> \u2022 Weight and HbA1c changes were modest (\u22126 kg vs \u22122 kg; NS).<\/span><\/div>\n<div><span> 4. Safety and Tolerability:<\/span><\/div>\n<div><span> \u2022 Metformin was generally well-tolerated.<\/span><\/div>\n<div><span> \u2022 12 patients (\u224825%) discontinued the drug, often because they felt asymptomatic.<\/span><\/div>\n<div><span> 5. Interpretation:<\/span><\/div>\n<div><span> \u2022 Benefit appears independent of weight or glycemic effects.<\/span><\/div>\n<div><span> 6. Mechanistic Insight:<\/span><\/div>\n<div><span> \u2022 Effect likely through AMP-activated protein kinase (AMPK) activation, a key cellular \u201cself-protection\u201d pathway.<\/span><\/div>\n<div><span> \u2022 Metformin may have anti-arrhythmic properties beyond glucose lowering.<\/span><\/div>\n<div><span> 7. Context and Outlook:<\/span><\/div>\n<div><span> \u2022 Despite newer agents (GLP-1 agonists, SGLT2 inhibitors), metformin remains cheap, safe, and mechanistically plausible for repurposing.<\/span><\/div>\n<div><span> 8. Caveats:<\/span><\/div>\n<div><span> \u2022 Small sample size, open-label design, high dropout rate \u2192 exploratory, not definitive.<\/span><\/div>\n<div><\/div>\n<div>Quote:<\/div>\n<div><\/div>\n<div>\u201cEven with the caveats, it\u2019s worth seeing if the old dog can learn new tricks.\u201d \u2014 George Schwartz, MD, PhD<\/div>\n<div><\/div>\n<div><a href=\"https:\/\/click.mail.medscape.com\/?qs=1933f8ddacb7b76bb784178c00e15afc5b310e75e9267db7af8583b8db99f533b97539bd69fa0318e0b2db2c46108f53d8c039e10c5e1ebd4a85f8fadce403d5\">https:\/\/click.mail.medscape.com\/?qs=1933f8ddacb7b76bb784178c00e15afc5b310e75e9267db7af8583b8db99f533b97539bd69fa0318e0b2db2c46108f53d8c039e10c5e1ebd4a85f8fadce403d5<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Metformin for Atrial Fibrillation \u2014 AHA 2025 (META-AF Trial) Source: AHA\u00a0 Medical News, AHA Scientific Sessions 2025 ( Nov 11, 2025) Key Points 1. Background: \u2022 Metformin, a long-used antidiabetic drug, may help reduce recurrent atrial arrhythmias after catheter ablation in overweight or obese patients without diabetes. 2. Study Design: \u2022 META-AF was a randomized, [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-9175","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9175"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9175\/revisions"}],"predecessor-version":[{"id":9176,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9175\/revisions\/9176"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}